CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
56.88
-1.30 (-2.23%)
At close: Dec 5, 2025, 4:00 PM EST
57.17
+0.29 (0.52%)
After-hours: Dec 5, 2025, 7:59 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 71.5, with a low estimate of 32 and a high estimate of 120. The average target predicts an increase of 25.70% from the current stock price of 56.88.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 7 | 6 | 6 | 6 | 6 | 7 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $82 → $74 | Strong Buy | Maintains | $82 → $74 | +30.10% | Nov 26, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $87 → $77 | Strong Buy | Maintains | $87 → $77 | +35.37% | Nov 12, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $42 → $50 | Hold | Maintains | $42 → $50 | -12.10% | Nov 11, 2025 |
| Baird | Baird | Hold Maintains $52 → $44 | Hold | Maintains | $52 → $44 | -22.64% | Nov 11, 2025 |
| Needham | Needham | Strong Buy Maintains $81 → $80 | Strong Buy | Maintains | $81 → $80 | +40.65% | Nov 10, 2025 |
Financial Forecast
Revenue This Year
15.58M
from 37.31M
Decreased by -58.24%
Revenue Next Year
128.37M
from 15.58M
Increased by 723.84%
EPS This Year
-6.32
from -4.34
EPS Next Year
-4.14
from -6.32
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 112.0M | 1.5B | ||||
| Avg | 15.6M | 128.4M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 200.0% | 9,699.8% | ||||
| Avg | -58.2% | 723.8% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.22 | 2.76 | ||||
| Avg | -6.32 | -4.14 | ||||
| Low | -6.72 | -6.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.